Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × evolocumab × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Endocrine 1

Conditions

Multiple Endocrine Neoplasia Type 1 1 Coronary Disease 1

Interventions

Everolimus 20 lutetium Lu 177 dotatate 10 pasireotide 9 Octreotide 8 surufatinib 7 lanreotide 7 pembrolizumab 5 amino-acid, glucose, and electrolyte solution 5 Sunitinib 5 Paclitaxel 5 Nivolumab 5 Injections 5 Carboplatin 5 3-Iodobenzylguanidine 5 relacorilant 4 fosbretabulin 4 Thyrotropin Alfa 4 Temozolomide 4 Fulvestrant 4 Data Collection 4 Cisplatin 4 selpercatinib 3 dabrafenib 3 Mifepristone 3 Etoposide 3 Corlux 3 Cabergoline 3 177Lu-octreotide, DOTA(0)-Tyr(3)- 3 vandetanib 2 trametinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03872401 2025-11-10

VESALIUS-CV

Amgen

Phase 3 Completed

12,301 enrolled

Coronary Disease, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡